SGMT (Sagimet Biosciences) Research & Development: $30.71 Mil (TTM As of Mar. 2026)


SGMT Sagimet Biosciences Inc SGMT
10 GF Score
Price $7.06
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Research & Development?

Sagimet Biosciences SGMT +2.84% 10 Research & Development is $30.71 Mil as of Mar. 2026. GuruFocus rates SGMT with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sagimet Biosciences's Research & Development for the three months ended in Mar. 2026 was $7.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $30.71 Mil.

Sagimet Biosciences  (NAS:SGMT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sagimet Biosciences Research & Development Related Terms

Sagimet Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Research & Development Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 19.34 24.92 19.78 38.44 39.05

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.34 7.25 9.73 6.73 7.00
SGMT
10GF Score
Sagimet Biosciences Inc SGMT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $30.71 Mil mean?
Sagimet Biosciences (SGMT) has a Research & Development of $30.71 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Research & Development too high?
Sagimet Biosciences' current Research & Development is $30.71 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Research & Development compare to NGNE and UPB?
Sagimet Biosciences' Research & Development of $30.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Research & Development is $30.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (SGMT) has a current Research & Development of $30.71 Mil. The current Research & Development is $30.71 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sagimet Biosciences (SGMT), the current Research & Development is $30.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for SGMT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price